HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

VPA-induced recurrent pancreatitis in a cystic fibrosis carrier.

Abstract
A 4.5 years old male with myoclonic epilepsy on Valproic acid (VPA) monotherapy, developed an acute pancreatitis. The discontinuation of VPA and substitution with Levetiracetam was followed by clinical improvement but a relapse of the pancreatitis was noted one month later. The investigation excluded a structural abnormality but revealed a heterozygous CTFR mutation. The contribution of the CTFR mutation on this VPA-induced recurrent pancreatitis cannot be ignored.
AuthorsArgirios Dinopoulos, Olga Karapanou, Efi Alexopoulou, Maria Tzetis, Achileas Attilakos, Andreas Fretzayas
JournalEuropean journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society (Eur J Paediatr Neurol) Vol. 15 Issue 5 Pg. 453-5 (Sep 2011) ISSN: 1532-2130 [Electronic] England
PMID21778093 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Anticonvulsants
  • Valproic Acid
Topics
  • Anticonvulsants (adverse effects)
  • Child, Preschool
  • Cystic Fibrosis (genetics)
  • Epilepsies, Myoclonic (drug therapy, genetics)
  • Genetic Carrier Screening
  • Humans
  • Male
  • Pancreatitis (chemically induced, diagnostic imaging, genetics)
  • Ultrasonography
  • Valproic Acid (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: